PLAU and breast carcinoma: Collectively, our data indicate that counteracting uPA‐PAI‐1 heteromerization by a small‐molecule inhibitor effectively interferes with the trafficking of pro‐tumorigenic neutrophils in experimental breast cancer and subsequently attenuates disease progression.